Local view for "http://purl.org/linkedpolitics/eu/plenary/2013-10-22-Speech-2-234-750"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20131022.26.2-234-750"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"I welcome the referral of this report back to committee. Innovation, consumer protection and the protection of EU jobs all need to be balanced. Like the in vitro devices regulation this directive also aims to address inconsistencies in Member Statesʼ interpretation of current rules, thus increasing the protection of public health and safety, removing obstacles to the internal market, etc. And similarly to my explanation of vote on the Liese Report I would like to voice concerns concerning the prescriptive nature of the report and the need to ensure that life-saving devices make it to the market as quickly as is safely possible. We cannot allow bureaucracy to slow down medical progress. I welcome the rejection by the Committee on the Environment, Public Health and Food Safety of the ‘preliminary marketing authorisationʼ as that would hinder the speed of medical progression; it would also cost the EU its innovative edge on the world market. I also welcome the increased level of transparency that this directive will ensure, as this will help to combat the counterfeit manufacturer of such products."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples